preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Lipopolysaccharide biosynthesis
inflammatory bowel disease
Lipopolysaccharide biosynthesis has meaningful literature visibility in inflammatory bowel disease, but the current evidence mix suggests a substantial risk of overclaiming.
Lipopolysaccharide biosynthesis shows a moderate evidence base in inflammatory bowel disease, with multiple central papers and additional supporting literature.
lipopolysaccharide_biosynthesis
Credibility score
47
Human translation
1/5
Reproducibility
4/5
Novelty
3/5
Actionability
2/5
Credibility 47Human translation 1/5Reproducibility 4/5Novelty 3/5Actionability 2/5
Why this scores the way it does
- moderate central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
Internal review flags
1 flagsPrimary central evidence
9 papersHuman ALPI deficiency causes inflammatory bowel disease and highlights a key mechanism of gut homeostasis.
2018EMBO molecular medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Differentially Abundant Bacterial Taxa Associated with Prognostic Variables of Crohn's Disease: Results from the IMPACT Study.
2020Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbial Signature in Adipose Tissue of Crohn's Disease Patients.
2020Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Identification of a choroid plexus vascular barrier closing during intestinal inflammation.
2021Science (New York, N.Y.)
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Acupuncture improves the symptoms, intestinal microbiota, and inflammation of patients with mild to moderate Crohn's disease: A randomized controlled trial.
2022EClinicalMedicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intestinal Permeability and Depression in Patients with Inflammatory Bowel Disease.
2022Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease.
2024European journal of gastroenterology & hepatology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Gallic acid attenuates LPS-induced inflammation in Caco-2 cells by suppressing the activation of the NF-κB/MAPK signaling pathway.
2024Acta biochimica et biophysica Sinica
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Ex Vivo Modeling and Pharmacological Modulation of Tissue Immune Responses in Inflammatory Bowel Disease Using Precision-Cut Intestinal Slices.
2025European journal of immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Supporting primary evidence
1 papersDeep Sequencing of Crohn's Disease Lamina Propria Phagocytes Identifies Pathobionts and Correlates With Pro-Inflammatory Gene Expression.
2025Inflammatory bowel diseases
Human primary paper with plausible association relevance to the disease context.
Preclinical supporting evidence
28 papersSerum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease.
2007Inflammatory bowel diseases
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bidirectional Regulation of Circadian Disturbance and Inflammation in Inflammatory Bowel Disease.
2017Inflammatory bowel diseases
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model.
2018EBioMedicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2 Macrophage Polarization and Gut Microbial Homeostasis.
2019Cell reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Lipopolysaccharides modulate intestinal epithelial permeability and inflammation in a species-specific manner.
2020Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Paeoniflorin Prevents Intestinal Barrier Disruption and Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in Caco-2 Cell Monolayers.
2019Inflammation
Disease-relevant preclinical or model-based paper useful as supporting evidence.
NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-κB signaling.
2019Cell death & disease
Disease-relevant preclinical or model-based paper useful as supporting evidence.
PIK3R3 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease.
2020International immunopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation.
2021Nature immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Antibacterial and Immunosuppressive Effects of OPS-2071, a Candidate Therapy for Inflammatory Bowel Disease.
2022Digestive diseases and sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
DSS-induced inflammation in the colon drives a proinflammatory signature in the brain that is ameliorated by prophylactic treatment with the S100A9 inhibitor paquinimod.
2021Journal of neuroinflammation
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Ganluyin ameliorates DSS-induced ulcerative colitis by inhibiting the enteric-origin LPS/TLR4/NF-κB pathway.
2022Journal of ethnopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis.
2022Theranostics
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Biallelic TLR4 deficiency in humans.
2023The Journal of allergy and clinical immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Omentin-1 ameliorates experimental inflammatory bowel disease via Nrf2 activation and redox regulation.
2023Life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease.
2023PloS one
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Amelioration of colitis progression by ginseng-derived exosome-like nanoparticles through suppression of inflammatory cytokines.
2023Journal of ginseng research
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Effect of Extracelluar Vesicles Derived from Akkermansia muciniphila on Intestinal Barrier in Colitis Mice.
2023Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Synthesis and Anti-Inflammatory Bowel Disease Activity of Pterostilbene Derivatives.
2024Chemistry & biodiversity
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Oleanolic acid 28-O-β-D-glucopyranoside: A novel therapeutic agent against ulcerative colitis via anti-inflammatory, barrier-preservation, and gut microbiota-modulation.
2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Galactooligosaccharides and Limosilactobacillus reuteri synergistically alleviate gut inflammation and barrier dysfunction by enriching Bacteroides acidifaciens for pentadecanoic acid biosynthesis.
2024Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Effects of water-insoluble wheat bran-fraction powder on disease activity and caecal microbiota in dextran sodium sulphate-induced inflammatory bowel disease mouse model.
2024Molecular biology reports
Disease-relevant preclinical or model-based paper useful as supporting evidence.
AhR-Induced Anti-Inflammatory Effects on a Caco-2/THP-1 Co-Culture Model of Intestinal Inflammation Are Mediated by PPARγ.
2024International journal of molecular sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Baicalin n-butyl ester alleviates inflammatory bowel disease and inhibits pyroptosis through the ROS/ERK/P-ERK/NLRP3 pathway in vivo and in vitro.
2025Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Glycine tabacina extract alleviates inflammatory bowel disease via NF-κB, JNK and Nrf2 signaling pathways.
2025Journal of ethnopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Combination therapy using intestinal organoids and their extracellular vesicles for inflammatory bowel disease complicated with osteoporosis.
2025Journal of orthopaedic translation
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Magnoflorine alleviates colitis-induced anxiety-like behaviors by regulating gut microbiota and microglia-mediated neuroinflammation.
2025Microbiome
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel disease.
2025World journal of gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
15 papersThe role of heme oxygenase and carbon monoxide in inflammatory bowel disease.
2010Redox report : communications in free radical research
Relevant review or meta-analysis for the signal-disease area.
Nutrition and growth in inflammatory bowel disease.
2013World review of nutrition and dietetics
Relevant review or meta-analysis for the signal-disease area.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
2020Autophagy
Relevant review or meta-analysis for the signal-disease area.
The Relationship Between Gut Microbiota and Inflammatory Diseases: The Role of Macrophages.
2020Frontiers in microbiology
Relevant review or meta-analysis for the signal-disease area.
Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body.
2021Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Role of the IL23/IL17 Pathway in Crohn's Disease.
2021Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
The influence of the gut microbiota on the bioavailability of oral drugs.
2021Acta pharmaceutica Sinica. B
Relevant review or meta-analysis for the signal-disease area.
Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease.
2022Journal of advanced research
Relevant review or meta-analysis for the signal-disease area.
The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Intestinal phages interact with bacteria and are involved in human diseases.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO.
2023Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review.
2024Internal and emergency medicine
Relevant review or meta-analysis for the signal-disease area.
Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies.
2023Thrombosis research
Relevant review or meta-analysis for the signal-disease area.
Microbiota and Lipotoxicity.
2024Advances in experimental medicine and biology
Relevant review or meta-analysis for the signal-disease area.
Regulatory roles of intestinal CD4+ T cells in inflammation and their modulation by the intestinal microbiota.
2025Gut microbes
Relevant review or meta-analysis for the signal-disease area.